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abstract
Three commercial brands of Swedish snus (SWS), an experimental SWS, and the 2S3 reference moist snuff were 
each tested in four in vitro toxicology assays. These assays were: Salmonella reverse mutation, mouse lymphoma, in 
vitro micronucleus, and cytotoxicity. Water extractions of each of the 5 products were tested using several different 
concentrations; the experimental SWS was also extracted using dimethyl sulfoxide (DMSO). Extraction procedures 
were verified by nicotine determinations. Results for SWS in the mutagenicity assays were broadly negative: there 
were occasional positive responses, but these were effectively at the highest concentration only (concentrations 
well above those suggested by regulatory guidelines), and were often associated with cytotoxicity. The 2S3 
reference was unequivocally positive in one of the three conditions of the micronucleus assay (MNA), at the highest 
concentration only. Positive controls produced the expected responses in each assay. The SWS data are contrasted 
with data reported for combusted tobacco in the form of cigarettes, where strongly positive responses have been 
routinely reported for mutagenicity and cytotoxicity. These negative findings in a laboratory setting concur with the 
large amount of epidemiological data from Sweden, data showing that SWS are associated with considerably lower 
carcinogenic potential when compared with cigarettes.
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Introduction
Swedish snus (SWS) are moist to semi-moist, ground, 
oral tobacco products (Rutqvist et al., 2011), which are 
often placed in “tea-bag” style packaging which consum-
ers usually place behind their upper lip. The products 
are made from mainly air-cured tobaccos, water, salt, 
and flavor additives; they are “pasteurized” in a propri-
etary heat treatment process which satisfies the hygienic 
requirements of the Swedish Food Act (Rutqvist et al., 
2011). Data from Swedish and US epidemiology studies 305  C. R. E. Coggins et al.
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(Lee and Hamling, 2009; Colilla, 2010) have shown that 
the use of SWS and other “moist snuff” products have 
effectively no effect on a broad range of cancers and 
other diseases (Lee, 2011), a finding in direct contrast 
with findings repeatedly reported elsewhere for com-
busted tobacco products such as cigarettes (IARC, 2004; 
US Department of Health and Human Services, 2004).
Epidemiology data have also shown that SWS has 
been used by many smokers as an aid to quit smoking, 
with snus use being associated with an increased prob-
ability of being a former smoker (Lund et al., 2011). The 
efficacy of SWS in smoking cessation was recently dem-
onstrated in two recent (but quite small) clinical trials 
(Fagerström et al., 2011; Joksic et al., 2011). SWS are very 
different from smokeless tobacco products (STP) used 
in regions other than Scandinavia and North America, 
for example the Sudanese “toombak” (Idris et al., 1998). 
Therefore, we agree that “oral tobacco products should 
not be categorized together when considering the public 
health implications of their use” (Stanfill et al., 2011).
Genetic toxicology testing, the study of chemical, 
physical or biological agents that may interact with DNA 
resulting in genetic changes,  has been a widely used 
procedure for several decades (Clive et al., 1972; Ames 
et al., 1973), the active principle being that short-term 
tests involving genetic changes may be indicative of 
carcinogenic risk in laboratory animals and in humans. 
The tests are primarily used on individual compounds 
(e.g. a novel pharmaceutical), largely as an early 
stage safety evaluation (if the test produces a positive 
finding, then there probably will be no further work 
performed on that compound). It is usual to conduct a 
complementary battery of tests for each compound and 
to include tests in both bacterial and mammalian cells. A 
typical approach would be to use the bacterial (usually 
Salmonella typhimurium) reverse-mutation or “Ames” 
assay (Ames et al., 1973; Ames et al., 1975; McCann et 
al., 1975), with additional tests for chromosome damage 
and aneuploidy (Kirkland et al., 2005; Kirkland et al., 
2011). Data on these latter endpoints are often obtained 
using the micronucleus assay (MNA) and the mouse 
lymphoma assay (MLA); there are recent suggestions 
that the only tests needed are S. typhimurium and in vitro 
micronucleus (Pfuhler et al., 2007; Kirkland et al., 2011). 
There are well-established international guidelines on 
how to perform each of these assays (OECD, 1997a,b,c), 
including the suggestion that “wherever possible, the use 
of an aqueous solvent/vehicle be considered first.”
A related in vitro test that is commonly used in com-
bination with the above assays is the neutral red uptake 
(NRU) assay (Nemes et al., 1979), a test for cytotoxic-
ity (Borenfreund and Puerner, 1985). Cytotoxicity is a 
major concern in genotoxicity assays (dead cells cannot 
mutate) and this factor has the potential to confound 
the interpretation of negative results. Compared to the 
assays listed above, only limited guidelines are available 
on the NRU assay (Andreoli et al., 2003; King and Jones, 
2003).
Combusted tobacco in the form of cigarette smoke 
condensate (CSC) has been shown to be highly active in 
a number of in vitro toxicology systems (DeMarini, 2004; 
DeMarini et al., 2008), particularly in the Salmonella 
mutagenicity test for the TA98 and TA100 strains in the 
presence of the Aroclor™ 1254 induced mammalian 
(rat) liver post-mitochondrial fraction (S9) (Rickert   
et al., 2007; Patskan et al., 2008; Gaworski et al., 2010). The 
MLA has also been used with CSC, and again the mixture 
has been found to be highly mutagenic (Schramke et 
al., 2006; DeMarini et al., 2008; Werley et al., 2008). An 
in vitro MNA for use with Chinese hamster fibroblast 
cells has been developed to use whole smoke and differ-
ent components of this complex mixture (Okuwa et al., 
2010). Both particulate and vapor phases of smoke from 
a reference cigarette generated significant responses in 
this assay. The NRU assay has also been used routinely 
in the comparative evaluations of both the gas-vapor 
and particulate phases of cigarette smoke (Patskan et al., 
2008; Gaworski et al., 2010).
The present study was performed to determine 
whether SWS are active in the in vitro toxicology assays 
classically used to predict carcinogenicity in humans. 
Although there are published reports on the in vitro 
toxicology of SWS (Jansson et al., 1991), the products 
evaluated and the tests available in a publication from 
20 years ago are quite different from those available 
today. In particular, the MLA does not appear to have 
been used previously with SWS. Also, concentrations of 
tobacco-specific nitrosamines, considered by some to be 
very important in STP (Österdahl et al., 2004; IARC, 2007; 
Scientific Committee on Emerging and Newly Identified 
Health Risks, 2008; World Health Organization, 2008; 
Stanfill et al., 2011), are now very much lower in SWS 
than they were 20 years ago, probably the result of altered 
manufacturing processes (Rutqvist et al., 2011).
Materials and methods
SWS and control samples
The following commercial SWS (manufactured by 
Swedish Match, Stockholm, Sweden) were tested: General 
Original Portion Large (hereafter abbreviated as “G”), 
Catch White Portion Large, Licorice (“CPS”), and Catch 
Dry White Portion Mini, Licorice (“CDM”). An experi-
mental SWS similar to CDM, but with experimental fla-
voring agents, was also tested (hereafter abbreviated as 
“CDM2”). The 2S3 reference moist snuff (North Carolina 
Agricultural Research Service, 2006; Borgerding et al., 
2009; Johnson et al., 2009) was also included. Table 1 
provides results of chemical analyses of the 5 different 
test materials, and compares these with the GothiaTek® 
standard (Rutqvist et al., 2011).
Extraction methods
The G, CPS, CDM and 2S3 samples were only tested 
with extractions using sterile, purified water; the CDM2 
samples were tested using both water extractions and The in vitro toxicology of Swedish snus  306
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extractions with sterile, anhydrous dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich, Poole, UK). DMSO was use as 
a second extraction agent for “CDM2” , because of the 
inclusion in this product of some experimental flavoring 
agents with limited water solubility.
Extracts were prepared using the following procedure 
at concentrations of 500 mg of tobacco product per ml, 
and conducted using sterile containers and solutions, 
in order to minimise contamination from external 
sources. Appropriate numbers of sachets of SWS were 
cut approximately in half, and both the contents and 
the sachets were weighed and mixed with appropriate 
volumes of water or DMSO to produce the required w/v 
concentration. If the tobacco was not finely divided then 
brief homogenisation was performed. Extractions were 
performed for 24 h at 37°C, with shaking. At the end of 
the 24 h extraction period, extracts were centrifuged at 
approximately 1800g for 30 min, and heavy particulates 
removed by decanting off the supernatant. The 
supernatant was then centrifuged at 25,000g for 30 
min, and fine particulates removed by decanting off the 
supernatant. The final supernatant was adjusted to pH 7.4 
± 0.2 with hydrochloric acid or sodium hydroxide (water 
extracts only). The resulting extracts were filter-sterilized 
using a 0.2 μm pore size filter (pre-filtering using a 
larger pore size was performed where required). Where 
extracts were prepared in two or more separate flasks, 
extracts were pooled prior to use in the assay. Aliquots 
of extracts were stored at approximately −80°C, and used 
within 3 months of extraction. Since extracts of SWS and 
reference products were each prepared according to the 
above methodology, with the particulate matter removed 
prior to assay, stated concentrations for these extracts 
should be considered to be in terms of equivalent weight 
of test material, corresponding to the concentration of 
test material present during the extraction phase.
For the Salmonella assays, treatments were performed 
using additions of 0.5 ml water extract per plate or 0.1 ml 
of DMSO extract per plate. For the other assays, treat-
ments were performed using 10% v/v additions of water 
extract and 1%, 1.5%, or 2% v/v additions of the DMSO 
extract.
Nicotine contents
Nicotine concentrations were assessed using high-
performance liquid chromatography; extraction blanks 
were used as negative controls in each assay system 
(Tambwekar et al., 2003). Three additional concentra-
tions (200, 300 and 400 mg/ml) were used in addition to 
that used for the toxicology testing (500 mg/ml).
In vitro assays
The four assays used were the S. typhimurium reverse-
mutation assay, the MLA, an in vitro micronucleus assay 
(MNAvit), and the NRU assay.
Ames assay
Extracts were assessed in a bacterial mutation assay 
system, using S. typhimurium tester strains TA98 (frame-
shift), TA100 (base-pair substitution), TA102 (base-pair 
substitution), TA1535 (base-pair substitution) and 
TA1537 (frameshift) using pre-incubation methodol-
ogy. Bacteria were originally obtained from the UK 
National Centre for Type Cultures and from Glaxo Group 
Research Ltd. Testing was performed in the absence and 
presence of S9 (Molecular Toxicology Inc., Boone, NC), 
as described in OECD guideline 471 (OECD, 1997a). Six 
concentrations were used for the water extracts: 0.08, 
Table 1.  Characteristics of the Swedish snus and the reference product, compared with the GothiaTek standard.
Parameter Units G* CPS* CDM* CDM2* 2S3** GothiaTek†
Serving size g 1.0 1.0 0.3 0.3
Water % 46.1 48.2 24.0 23.5 54.7
Sodium chloride % 9.6 13.1 12.1 10.0 7.32
pH units 8.4 8.4 7.5 7.2 7.42
Nitrite ppm 2 1 1 2 11.2 7.0
Nicotine % 1.5 1.6 2.1 2.1 1.38
NNNa ppm 1.1 1.2 0.9 0.8 3.50
NNKb ppm 0.3 0.4 0.2 0.2 0.91
NATc ppm 0.8 0.8 0.6 0.6 2.35
NABd ppm <0.1 <0.1 <0.1 <0.1 0.18
TSNAe ppm 2.2 2.4 1.7 1.6 6.95 10.0
Arsenic ppm 0.14 0.14 0.14 0.11 0.20 0.5
Cadmium ppm 0.48 0.48 0.57 0.60 1.56 1.0
Chromium ppm 0.80 1.10 1.60 0.92 1.31 3.0
Lead ppm 0.32 0.33 0.30 0.27 0.33 2.0
Nickel ppm 1.2 1.4 2.0 1.6 1.88
B[a]Pf ppb 1.9 1.9 1.3 1.3 79 20.0
*Data from unpublished Swedish Match analyses. See text for explanation of these abbreviations. **Data from Borgerding et al. 2009. 
†Data from Rutqvist et al. 2011.
aN-nitrosonornicotine. b4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. cN-nitrosoanatabine. dN-nitrosoanabasine. eTobacco-specific 
nitrosamines (sum of NNN, NNK, NAB and NAT). fBenzo[a]pyrene.307  C. R. E. Coggins et al.
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0.40, 2, 10, 50 and 250 mg per plate equivalent (OECD 
guideline 471 recommends a maximum test concentra-
tion for soluble non-cytotoxic substances of 5 mg/plate). 
Six concentrations were also used for the DMSO extract: 
0.016, 0.08, 0.40, 2, 10 and 50 mg per plate equivalent. 
Three plates were used for each treatment and for the 
positive controls, with five for the solvent control.
The highest concentrations used were considered to 
be the highest achievable concentrations in this assay, 
using the highest extraction concentration that could 
practically be extracted from the test materials, and the 
largest volume additions that the assay system could tol-
erate for each solvent.
The following positive control substances (Sigma-
Aldrich) and their concentrations were used for the dif-
ferent tester strains and S9 conditions: 2-nitrofluorene 
(2NF, TA98, −S9, 5 μg/plate), sodium azide (NaN3, TA100, 
TA1535, both −S9, 2 μg/plate), 9-aminoacridine (AAC, 
TA1537, −S9, 50 μg/plate), mitomycin C (MMC, TA102, 
−S9, 0.2 μg/plate), benzo[a]pyrene (B[a]P, TA98, +S9, 10 
μg/plate) and 2-aminoanthracene (AAC, TA100, TA1535, 
TA1537, and TA102, all +S9, 5 μg/plate except for TA 102, 
20 μg/plate).
MLA assay
Extracts were assessed in duplicate cultures of mouse 
lymphoma L5178Y thymidine kinase (tk+/−) cells (a 
gift from Dr. D. Clive, Burroughs-Wellcome, NC), as 
described in OECD Guideline 476 (OECD, 1997c). 
Treatments were conducted using 3- and 24-h exposures 
in the absence of S9, and a 3-h treatment in the pres-
ence of S9 (Clive et al., 1995; Moore et al., 2006), using 
six concentrations for the water extractions (5, 10, 20, 30, 
40 and 50 mg/ml equivalent) and eight concentrations 
for the DMSO extractions (7.5, 15, 30, 45, 60, 65, 70 and 
75 mg/ml equivalent). Treatments were assessed for 
their effects on relative total growth (RTG) and mutant 
frequency (MF).
The positive controls (single plate, Sigma-Aldrich) 
used were 4-nitroquinoline 1-oxide (NQO, −S9 condi-
tion) and B[a]P (+S9 condition), at low and high concen-
trations of 0.05 and 0.1 μg/ml (NQO, 24 h), 0.15 and 0.20 
μg/ml (NQO, 3 h), and 2 and 3 μg/ml (B[a]P, both time 
points), respectively.
MNAvit assay
Extracts were assessed in duplicate cultures of Chinese 
hamster fibroblast V79 cells (a gift from Dr. E Massey, BAT, 
UK) in an in vitro MNA, according to OECD guidelines 
474 (OECD, 1997b) and 487 (OECD, 2007). Four plates 
were used for the solvent controls and two plates for the 
positive controls. The target number of cells to be exam-
ined was 1000 for each plate. Treatments were conducted 
using 3 h (pulse) treatments in the absence and presence 
of S9, followed by a 17-h recovery period (3 + 17), and 20 
h (continuous) treatment in the absence of S9. At least 
three concentrations were tested in addition to solvent 
controls, in the range 6.7–50 mg/ml for the water extracts 
and 0.27–7.5 mg/ml for the DMSO extracts.
The MNA assay detects clastogens and aneugens in cells 
that have undergone cell division during or after exposure 
to the test substance (Lorge et al., 2006). The assay typically 
uses protocols with and without the actin polymerization 
inhibitor cytochalasin B (a mycotoxin); however, we did 
not perform any testing without cytochalasin B. Addition 
of this compound prior to the targeted mitosis allows for 
the identification and selective micronucleus frequency 
in cells that have completed a single mitosis, because 
such cells are binucleate. Cytochalasin B (Sigma-Aldrich) 
inhibits cytokinesis (cell division), but not karyokinesis 
(nuclear division), resulting in the formation of binucleate 
cells. Thus, when micronuclei are only counted in 
binucleate cells, a true measurement of their induction 
can be obtained. Cytochalasin-B has been shown to 
have no effect on the overall assay (Lorge et al., 2006). 
Treatments were assessed for resulting counts of micro-
nucleated binucleate (MNBN) cells.
The positive controls (Sigma-Aldrich) used were NQO 
(0.30 μg/ml) and vinblastin (VIN, 0.004 μg/ml), for the 
−S9 condition, and cyclophosphamide (CPA, 8 μg/ml) 
for the +S9 condition.
NRU assay
Extracts were assessed in Balb/c 3T3 mouse fibroblast 
cells (Borenfreund and Puerner, 1985; Babich and 
Borenfreund, 1990), purchased from the European Cell 
and Culture Collection. Cytotoxicity was measured by 
assessment of NRU after 24 h of exposure, expressed as 
the per cent cell survival. The eight concentrations were 
0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 50 mg/ml for the 
water extracts and 0.04, 0.08, 0.16, 0.31, 0.63, 1.25, 2.5 
and 5 mg/ml for the DMSO extracts. Six replicates were 
performed for each concentration. The positive control 
used was sodium dodecyl sulfate (Sigma-Aldrich), used 
at a single concentration of 100 μg/ml.
Two experiments were performed: one compared 
samples “G” , “CPS” and “2S3” , and the other compared 
samples “CDM” , “CDM2” (water extraction), and “CDM2” 
(DMSO extraction).
Endpoint analyses
For the S. typhimurium analyses, we used pairwise 
comparisons of mean revertant counts with the solvent 
control, using Dunnett’s test and a significance level of 
P < 0.01. Dunnett’s test makes adjustments for multiple 
corrections: it ensures that the type 1 error rate will be 
fixed at the desired level by incorporating correction 
factors into the design of the test table. The significance 
level used here (<0.01 rather than <0.05 used elsewhere) 
is well-established and is widely used for bacterial muta-
tion assay data. An estimate was made of dose response, 
considered to be present if the two highest concentra-
tions both produced significant differences from the 
solvent controls. We also considered the twofold rule 
(Cariello and Piegorsch, 1996) to infer positive results, The in vitro toxicology of Swedish snus  308
© 2012 Informa Healthcare USA, Inc. 
modified to a threefold rule for tester strains TA1535 and 
TA1537 because of their relatively low number of back-
ground revertants (c. 10–20 per plate).
For the MLA we used pairwise comparisons of mean 
MF values with those in the solvent controls, using 
Dunnett’s test and a significance level of P < 0.05. Linear 
trends in MF values were evaluated using χ2-tests and a 
significance level of P < 0.05. We also considered mean 
MF values that were at least 126 revertants per million 
cells greater than the mean MF in the solvent controls 
(termed the global evaluation factor) (Moore et al., 2006).
In the MNAvit study, a binomial dispersion test was 
used to determine homogeneity between replicates. This 
was followed by the use of Fisher’s exact test and a sig-
nificance level of P < 0.05 to compare numbers of MNBN 
cells in treated groups with those in the concomitant 
solvent control group. We also considered whether the 
results obtained for percentages of MNBN cells were 
higher than those seen in the historical solvent control. 
These historical values (from 53 prior studies) were 2.9% 
(3 + 17, −S9), 2.8% (3 + 17, + S9), and 3.0% (0 + 20, −S9).
For the NRU assay, pairwise comparisons of cell sur-
vival rates were made at the highest extract concentra-
tion, using SigmaPlot version 11.2 (San Jose, CA) and a 
significance level of P < 0.05.
Results
Nicotine determination
Excellent consistency in nicotine concentrations was 
obtained between separate water extracts, indicating that 
the extraction methodology provided consistent levels of 
extracted material. Estimated nicotine recovery levels 
(based on information provided on nicotine levels of the 
different materials used) from 200, 300, 400 and 500 mg/
ml equivalent water extracts were 84%, 78%, 76% and 
73%, indicating that nicotine content does continue to 
increase proportionately over these increasing extraction 
concentrations, with only a relatively small reduction in 
recovery efficiency.
Ames assay
Results of the S. typhimurium mutagenicity assays for 
sample “G” are given as Table 2, with separate listings for 
the −S9 and +S9 conditions. Results for the other samples 
are provided in the supplementary material.
For both conditions, there were several mean rever-
tant counts that reached statistical significance when 
compared with the solvent control; these counts were 
often limited to the highest concentration (i.e. there was 
little or no evidence for a dose-response relationship). 
There were three cases where the two highest concen-
trations were both significantly greater than the solvent 
control: sample “G” for TA102 in the −S9 condition (Table 
2), sample “CDM” for TA1537 in the −S9 condition, and 
sample “CDM2” in the water extraction, TA102, −S9 con-
dition. There were only two cases of a doubling (or a tri-
pling) of the mean value for the solvent control, but these 
were not the same two cases as those described above. 
The cases here were sample “G” , TA1535, −S9 (mean of 45 
revertants compared to 11, a factor of 4.1, Table 2), and 
sample “CPS” , TA1535, −S9 (mean of 43 revertants com-
pared to 11, a factor of 3.9). The two different assessment 
methods thus provided different indications of possible 
mutagenic activity; both of these indications were effec-
tively limited to the highest concentration being tested.
With one exception, mean revertant counts for the 
positive controls were in the range of 5-to-70-fold 
Table 2.  Results of the Salmonella mutagenesis assay with water extracts of Swedish snus sample “G” (−S9 and +9 conditions).
Treatment (mg/ml) TA98 TA100 TA1535 TA1537 TA102
0 −S9 17 ± 6 108 ± 4 11 ± 3 14 ± 3 288 ± 13
0.08 −S9 ND 93 ± 11 24 ± 7* 13 ± 3 311 ± 6
0.4 −S9 33 ± 3* 89 ± 10 19 ± 5 16 ± 5 313 ± 6
2 −S9 23 ± 2 97 ± 8 13 ± 3 16 ± 2 308 ± 23
10 −S9 17 ± 1 91 ± 13 16 ± 5 16 ± 6 313 ± 8
50 −S9 19 ± 5 83 ± 7 21 ± 8 18 ± 5 338 ± 15*
250 −S9 21 ± 6 122 ± 9 45 ± 10* 26 ± 6* 390 ± 30*
Positive control −S9 940 ± 210* 940 ± 84* 573 ± 22* 68 ± 9* 1573 ± 38*
0 +S9 27 ± 6 113 ± 6 20 ± 9 20 ± 4 262 ± 47
0.08 +S9 28 ± 5 82 ± 19 18 ± 4 17 ± 5 189 ± 75
0.4 +S9 27 ± 3 99 ± 6 17 ± 6 22 ± 4 200 ± 33
2 +S9 26 ± 2 92 ± 18 16 ± 1 15 ± 6 218 ± 86
10 +S9 29 ± 9 108 ± 14 15 ± 8 19 ± 6 216 ± 89
50 +S9 23 ± 10 79 ± 8 13 ± 5 19 ± 9 306 ± 24
250 +S9 43 ± 8 126 ± 12 43 ± 8* 40 ± 3* 323 ± 32
Positive control +S9 249 ± 56* 1159 ± 99* 185 ± 112* 74 ± 57* 1016 ± 170*
Data expressed as mean (±SD) revertant colonies per plate. Five replicates were used for the solvent control; three replicates were used 
for all other treatments. Bold type indicates a doubling (TA98, TA100, TA102) or a tripling (TA1535, TA1537) of the mean revertant count 
for the solvent control. Positive controls and the doses used are described in the text.
*Significantly different (P < 0.01) from the solvent control, using Dunnett’s test.
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significant increases over the mean for the solvent 
control for the −S9 condition and 4-to-9-fold for the +S9 
condition. The exception was for the DMSO extractions 
of sample “CDM2” with strain TA1537: for the +S9 
condition the mean value for the positive control was 2.9 
times higher than that for the solvent control.
MLA assay
The results of the MLA for sample “G” are given as Table 3, 
with separate listings for the 3-h treatments (both S9 
conditions) and the 24-h treatments (−S9 only). Results 
for the other samples are provided in the supplementary 
material.
There were several mean MFs that reached statistical 
significance when compared with the solvent control; 
these differences were sporadic with no apparent dose–
response relationship. There were two clear exceptions, 
both in the 24-h −S9 condition. The first was sample 
“CDM” , where the two highest treatments both had mean 
MFs that were significantly greater than the mean for the 
solvent control. The second was sample “CDM2” , water 
extraction, where the three highest treatments all had 
mean MFs that were significantly greater than the mean 
for the solvent control. Significant linear trends in MFs 
were noted for several of the 3-h +S9 and 24-h −S9 condi-
tions; none were observed for the 3-h −S9 condition.
There were two cases of mean MFs greater by at least 
126 revertants per million cells than the mean for the 
solvent control, and these were for the same samples 
as those noted above for conventional statistical signifi-
cance. The highest treatments for the 24-h−S9 condition 
with samples “CDM” and “CDM2” , water extraction, had 
mean MFs of 270 and 327, respectively, compared with 
the mean value for the solvent control group of 103.
The two positive responses described above were both 
associated with considerable toxicity: the RTGs for both 
at the highest concentration were only 8%, less than the 
suggested minimum of 10% (Moore et al., 2006).
Mean MFs for the positive controls (both doses) were 
in the range of 2-to-17-fold significant increases over the 
mean value for the solvent control and were considerably 
greater than the global evaluation factor.
MNAvit assay
Homogeneity testing did not reveal any major discrepan-
cies between replicates.
The results of the MNAvit assay for sample “G” are 
given as Table 4, with separate listings for the 3 + 17 
h treatments (both of the S9 conditions) and the 20 h 
treatment (the −S9 condition only). Results for the other 
samples are given in the supplementary material.
Table 3.  Results of the mouse lymphoma assay with water 
extracts of Swedish snus sample “G” (3-h and 24-h treatment).
Treatment (mg/ml) %RTG MF %RTG MF
0 (3-h) −S9 100 112 +S9 100 74.7
5 −S9 105 104 +S9 108 69.2
10 −S9 125 86.1 +S9 101 72.5
20 −S9 134 78.8 +S9 113 72.1
30 −S9 136 75.3 +S9 97 88.7
40 −S9 101 91.8 +S9 106 54.0
50 −S9 107 89.9 +S9 88 97.0
Positive control-L −S9 62 728* +S9 57 552*
Positive control-H −S9 83 533* +S9 30 992*
0 (24-h) −S9 100 147†
10 −S9 95 144
20 −S9 71 184
30 −S9 67 177
40 −S9 69 186
45 −S9 54 177
50 −S9 42 223*
Positive control-L −S9 67 288*
Positive control-H −S9 48 431*
RTG, Relative total growth; MF, Mutant frequency, the number of 
revertant cells × 10−6 viable cells 2 days after treatment.
Two replicates were used for each treatment, with only a single 
plate for the positive controls. Bold type indicates that the global 
evaluation factor (a mutant frequency of 126 × 10-6 revertant cells 
greater than the mutant frequency in the solvent control) was 
exceeded. Positive controls were 4-nitroquinoline-1-oxide for the 
−S9 condition and benzo[a]pyrene for the +S9 condition. See text 
for doses used.
*Significantly different (P < 0.05) from the solvent control, using 
Dunnett’s test. 
†A significant (P < 0.05) linear trend, using the χ2-test.
Table 4.  Results of the in vitro micronucleus assay with water extracts of Swedish snus sample “G” .
Dosing regimen (hours treatment + hours recovery, S9 status)
3 + 17, −S9 3 + 17, +S9 20 + 0, −S9
Dose MNBN Dose MNBN Dose MNBN
mg/ml Cells % mg/ml Cells % mg/ml Cells %
0 34 0.85 0 71 0.89 0 45 1.13
16.4 16 0.8 8.39 47 1.18 6.71 24 1.20
32 25 1.25 25.6 40 1.00 8.39 24 1.20
50 20 1.00 50 72 1.80* 10.5 27 1.35
NQO 35 2.42* CPA 235 5.88* VIN 30 55.6*
NQO 174 9.23*
MNBN, micro-nucleated binucleate cells; NQO, 4-nitroquinoline 1-oxide; CPA, cyclophosphamide; VIN, vinblastin. See text for doses 
used.
Two replicates were used for each treatment and for the positive controls; four replicates were used for the solvent controls. The target 
was 2000 binucleate cells per replicate. Bold type indicates values that exceeded the historical range for the solvent control (see text).
*Significantly different (P < 0.05) from the solvent control, as assessed by Fisher’s exact test. †excessive cytotoxicity.The in vitro toxicology of Swedish snus  310
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There were several incidences of MNBN incidences 
that reached statistical significance when compared with 
the concomitant solvent control; in only two cases did 
the incidences exceed the historical range for the solvent 
control. The first of these cases was for sample “CDM2” , 
water extraction, in the 3 + 17 h, −S9 condition. At the 
highest concentration tested the mean MNBN response 
was 4.1%, compared with 0.85% for the concomitant 
solvent controls and with 2.9% for historic solvent 
controls. However, there was considerable cytotoxicity 
(70%) associated with this response. The second case was 
the 2S3 reference product, in the 3 + 17 h, +S9 condition. 
At the highest concentration tested the mean MNBN 
response here was 4.08%, compared with 0.89% for the 
concomitant solvent controls and with 2.8% for historic 
solvent controls. Cytotoxicity was not excessive in this case 
(22%), and so the 2S3 response is unequivocally positive.
Positive controls produced responses that were sig-
nificantly increased when compared with concomitant 
solvent controls. With one exception, the positive con-
trol responses were also significantly increased when 
compared with historical solvent controls. The exception 
was NQO in the 3 + 17 h, −S9 condition, where the mean 
value (2.42%) was less than the historical mean value, 
even though it was almost threefold higher than the 
concomitant solvent control (comparable to the positive 
control for the TA1537 +S9 condition of the Ames assay). 
When used at the same dose in the 20 + 0 h, −S9 condi-
tion, NQO produced an approximately eightfold increase 
over concomitant solvent controls and an approximately 
threefold increase over historical solvent controls.
NRU assay
Results of the two experiments are presented as Figures 
1 and 2.
The increasing cytotoxicity (decreasing cell survival) of 
the extracts from samples “G” , “CPS” and “2S3” were very 
similar, with the lowest attained survival being approxi-
mately 75% (Figure 1). At the highest extract concentra-
tion, the mean cell survival for the “CPS” sample was 
significantly greater (by about 10%) than those for the “G” 
and “2S3” samples (Holm-Sidak test, P < 0.05, Figure 1).
The decline in cell survival in the “CDM” and “CDM2” 
(water extraction) samples with increasing extract con-
centration was effectively identical (Figure 2), with zero 
survival at the highest concentration. However, cell sur-
vival for the “CDM2” sample (DMSO extraction) at the 
highest concentration was 44% (Figure 2).
There was minimal cell survival with the positive control.
Discussion
We showed that various types of in vitro toxicology test-
ing, including those tests classically used to predict carci-
nogenicity in humans, are feasible for STP such as SWS. 
Positive control substances demonstrated that each of 
the tests was working correctly.
We also showed that for SWS in assays such 
as  S. typhimurium, mouse lymphoma and in 
vitro micronucleus, the results provided no clear 
biologically-relevant positive responses, as opposed to 
the statement of “poor performance” made by others 
(Johnson et al., 2009). In most cases the results for the 
reference moist snuff were also negative, but there was 
one unequivocally positive response. Using carefully 
controlled assays with positive controls, we showed 
that cytotoxicity can be controlled and indeed (with 
some exceptions) this was not a problem in the work 
we describe here. The broadly negative data presented 
here for SWS contrast strongly with data for cigarettes 
where the tobacco is combusted; for these products, 
substantial genotoxicity has been demonstrated 
repeatedly (DeMarini et al., 2008).
Normally, genetic toxicology data such as those 
we present here would be the first step in a toxicologi-
cal evaluation that would end with epidemiology. The 
reverse is the case here, with extensive epidemiology but 
Figure 1.  Results of the neutral red uptake assay with samples “G” , 
“CPS” and “2S3” . Means ± SD (n = 6). *Significantly different (P < 
0.05) from the other two means.
Figure 2. Results of the neutral red uptake assay with samples 
“CDM” and “CDM2” . Means ± SD (n = 6).311  C. R. E. Coggins et al.
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minimal genetic toxicology. Our work therefore repre-
sents a unique case of being able to “look back” on the 
toxicological evaluation process; it provides validation of 
the genetic testing of non-combusted tobacco products. 
Cigarette smoke on the other hand has shown strong evi-
dence of carcinogenicity by epidemiology and positive 
results from genetic toxicology tests.
A limitation of the work described here is the fact that 
a full set of chemical analyses was not made on the actual 
products tested (nicotine only was analyzed). However, a 
full set of analyses was made on identical products, and 
these data are presented in Table 1. Another limitation 
is the lack of agreement in the literature on the statisti-
cal criteria to be used to determine a positive response, 
particularly for the Salmonella mutagenicity assay where 
the OECD guidelines simply state that “there are several 
criteria for determining a positive result.” A further limi-
tation is our exclusive use of aqueous extracts, supple-
mented in one case with DMSO extracts. We are aware 
of published work with extractions using artificial saliva, 
and the use of alternative extraction agents may be an 
avenue for future work.
These broadly negative findings in a controlled 
laboratory setting add to the large amount of epide-
miological data from Scandinavia (Colilla, 2010; Lee, 
2011), data showing that SWS are associated with 
considerably lower carcinogenic potential when com-
pared with tobacco products involving combustion of 
the tobacco (US Department of Health and Human 
Services, 2004).
conclusions
For each of the assays, data obtained for negative and 
positive controls confirmed that the test systems were 
working correctly.
Ames assay
Extracts of the four SWS and the 2S3 reference did 
not induce clear increases in MF in five strains of S. 
typhimurium, both in the absence and in the presence 
of S9. Two different methods for evaluating the data 
produced conflicting results. The observed increases in 
revertant numbers were limited to extreme concentra-
tions of the test material (well in excess of concentrations 
required by regulatory guidelines, such as OECD 471), 
and so these findings are considered to be of limited rel-
evance to an overall risk assessment for SWS.
MLA assay
Extracts of the four SWS and the 2S3 reference did not 
induce clear increases in MF in L5178Y tk+/− cells, both 
in the absence and in the presence of S9. For the 3-h 
treatments, no increase in MFs over the global evaluation 
factor was noted. In two cases with the 24-h treatments, 
MFs were greater than the global evaluation factor. In 
each of these cases the RTG values were substantially 
reduced (indicating considerable cytotoxicity), so these 
findings are considered to be of limited relevance to an 
overall risk assessment for SWS.
MNAvit assay
Extracts of the four SWS did not show increased MNBN 
counts in Chinese hamster fibroblast cells, with an 
unequivocally positive result for the 2S3 reference at the 
highest dose in the 3 + 17 h +S9 condition.
NRU assay
No obvious differences were noted between the cytotox-
icity results noted in Balb/c 3T3 mouse fibroblast cells for 
the “G” , “CPS” and “2S3” samples, with the highest extract 
concentrations only producing approximately 75% cyto-
toxicity. Complete cytotoxicity was seen with the “CDM” 
and “CDM2” samples at the highest concentration, with 
some apparent reduction in cytotoxicity in the “CDM2” 
sample when DMSO extraction was used.
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